Myron Z. Holubiak - 19 Sep 2025 Form 4 Insider Report for CITIUS ONCOLOGY, INC. (CTOR)

Reporting relationship: Secretary, Director
Issuer ticker: CTOR
Reported as of: 19 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Sep 2025, 16:10:26 UTC
Prior SEC filing: 12 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Alexander M. Donaldson, by Power of Attorney

Key filing fact

Myron Z. Holubiak filed Form 4 for CITIUS ONCOLOGY, INC. (CTOR) on 23 Sep 2025.

Key facts

This page summarizes Myron Z. Holubiak's Form 4 filing for CITIUS ONCOLOGY, INC. (CTOR).
2 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 23 Sep 2025, 16:10.

Change

Previous filing in this sequence was filed on 12 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001199080 Primary reporting owner

HOLUBIAK MYRON Z

Relationship: Secretary, Director
Address: C/O CITIUS ONCOLOGY, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD
Signature: /s/ Alexander M. Donaldson, by Power of Attorney
Signature date: 23 Sep 2025

This filing has been restated. Open the amended filing.

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTOR transaction

Common Stock

Award

Transaction value: $0
Shares: +850,000
Change %
Price: $0.000000
Shares after: 850,000
Date: 19 Sep 2025
Ownership: Direct
Footnotes: F1

CTOR transaction

Common Stock

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 19 Sep 2025
Ownership: See footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTOR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 300,000
Date: 19 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $1.07
Footnotes: F3

CTOR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 50,000
Date: 19 Sep 2025
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $1.07
Footnotes: F3, F4

CTOR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,500,000
Date: 19 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,500,000
Exercise price: $2.15
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

Footnote F2

Represents restricted stock awards granted on September 19, 2025 to the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.

Footnote F3

These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

Footnote F4

These options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.

Footnote F5

These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.